JIA Registry - Abatacept


Clinical Trial Title

JIA Registry - Abatacept

Trial Status

Open to Enrollment

Start Date

March 15, 2013

Trial Type

Pediatric Rheumatology

Specific Condition

Juvenile Idiopathic Arthritis (JIA)


The purpose of this study is to examine the long-term safety of Abatacept for the treatment of juvenile idiopathic arthritis (JIA) in routine clinical practice, with particular in interest in the occurrence of serious infections, autoimmune disorders, and malignancies.

Eligibility Criteria

Ages Eligible for Study:  up to 17

Genders Eligible for Study:  Both

Inclusion Criteria:

  • Diagnosis of JIA (any subtype).
  • Age < 18 years at the time of enrollment.
  • Receiving Abatacept at the time of enrollment as per treating physician's decision.
  • Parent or legally acceptable representative willing to participate in the study and sign the informed consent.

IRB Number


Principal Investigator Name

Daniel Kingsbury, MD

Contact Name

Kristin Hickey



Contact E-Mail


Last Updated: Wednesday, September 18, 2013 01:27:45 PM